Skip to contentT
Thermo Fisher Scientific Inc.
T
TMOThermo Fisher Scientific Inc. Q2 2026 · 10-Q
Revenue$11.99B$11.99B+10.5% vs Q2 2025 Net Income$1.74B$1.74B+7.4% vs Q2 2025 EPS Diluted$4.68$4.68+9.3% vs Q2 2025 Operating Income$2,087,000,000+13.8% Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Thermo Fisher Scientific Inc. · CIK 97745 · Engraved from SEC EDGAR
derived
Free Cash Flowderived$1,675,000,000+51.6% Margins · derivedOperating margin17.4%+0.5 pt vs Q2 2025
Net margin14.5%−0.4 pt vs Q2 2025
ended Jun 27, 2026 · filed Jul 31, 2026 · 34 d after period end